Document is current

Article History

Received: 11 May 2023

Accepted: 30 July 2024

First Online: 21 August 2024

Declarations

:

: Xenograft studies were approved by the Institutional Animal Care and Use Committee of MD Anderson (00001032-RN03). This study was approved by the MD Anderson IRB (PA15-0499) or Seoul National University Hospital IRB (2310–165-1480) and conducted in agreement with the requirements of the Code of Federal Regulations and the IRB.

: All patients signed an IRB-approved consent form indicating their agreement to participate. The consent form includes the nature, objectives, and potential risks and benefits of the study and details the required length of follow-up, required tissue biopsies and blood sample collections, and the name of the principal investigator responsible for the protocol. The consent also specifies the patient’s right to accept or refuse treatment, terminate participation, and withdraw from the protocol. All data were collected in accordance with the human subjects research policies of MD Anderson and Seoul National University Hospital.

: Naoto T. Ueno and Jangsoon Lee have contracted research with Daiichi Sankyo. Seock-Ah Im reports advisory role for AstraZeneca, Daiichi-Sankyo, Eisai, Hanmi, Idience, Lilly, MSD, Novartis, Pfizer, Bertis, and Roche and has received research grants through her institution from AstraZeneca, Boryung Pharm, Daiichi-Sankyo, Daewoong Pharm, Eisai, Pfizer, and Roche. All other authors declare no competing interests.